BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22281054)

  • 1. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
    Lim PL; Zhou J; Ditangco RA; Law MG; Sirisanthana T; Kumarasamy N; Chen YM; Phanuphak P; Lee CK; Saphonn V; Oka S; Zhang F; Choi JY; Pujari S; Kamarulzaman A; Li PC; Merati TP; Yunihastuti E; Messerschmidt L; Sungkanuparph S;
    J Int AIDS Soc; 2012 Jan; 15(1):1. PubMed ID: 22281054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study.
    Saah AJ; Hoover DR; Peng Y; Phair JP; Visscher B; Kingsley LA; Schrager LK
    JAMA; 1995 Apr; 273(15):1197-202. PubMed ID: 7707627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Torres RA; Barr M; Thorn M; Gregory G; Kiely S; Chanin E; Carlo C; Martin M; Thornton J
    Am J Med; 1993 Dec; 95(6):573-83. PubMed ID: 8018144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
    Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
    Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aerosolized pentamidine, cotrimoxazole and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.
    Antinori A; Murri R; Ammassari A; De Luca A; Linzalone A; Cingolani A; Damiano F; Maiuro G; Vecchiet J; Scoppettuolo G
    AIDS; 1995 Dec; 9(12):1343-50. PubMed ID: 8605054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for failure of prophylaxis for Pneumocystis carinii pneumonia.
    Edge MD; Rimland D
    AIDS; 1999 May; 13(8):991-2. PubMed ID: 10371182
    [No Abstract]   [Full Text] [Related]  

  • 9. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
    D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
    AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies Infectieuses.
    May T; Beuscart C; Reynes J; Marchou B; Leclercq P; Borsa Lebas F; Saba J; Micoud M; Mouton Y; Canton P
    J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):457-62. PubMed ID: 8158539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
    Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
    Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV Outpatient Study (HOPS) Investigators.
    Moorman AC; Von Bargen JC; Palella FJ; Holmberg SD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Oct; 19(2):182-8. PubMed ID: 9768629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
    Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
    Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
    Helweg-Larsen J; Benfield T; Atzori C; Miller RF
    J Antimicrob Chemother; 2009 Dec; 64(6):1282-90. PubMed ID: 19858161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
    Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.
    Mallolas J; Zamora L; Gatell JM; Miró JM; Vernet E; Valls ME; Soriano E; SanMiguel JG
    AIDS; 1993 Jan; 7(1):59-64. PubMed ID: 8442918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
    Huang YS; Yang JJ; Lee NY; Chen GJ; Ko WC; Sun HY; Hung CC
    Expert Rev Anti Infect Ther; 2017 Sep; 15(9):873-892. PubMed ID: 28782390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity.
    Slavin MA; Hoy JF; Stewart K; Pettinger MB; Lucas CR; Kent SJ
    AIDS; 1992 Oct; 6(10):1169-74. PubMed ID: 1466849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.